Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis
- PMID: 40169704
- PMCID: PMC12125246
- DOI: 10.1038/s41423-025-01278-7
Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis
Abstract
Psoriasis patients who are obese tend to have serious clinical manifestations and poor responses to various biological agents in most cases. However, the mechanisms by which obesity exacerbates psoriasis remain enigmatic. In this study, we found that the abundance of systemic and localized cutaneous neutrophil extracellular traps (NETs) associated with the obesity-induced aggravation of psoriasis was positively correlated with disease severity and that the inhibition of NETs alleviated psoriatic dermatitis in obese mice. Mechanistically, we found that changes in fatty acid composition in obese subjects resulted in the deposition of saturated fatty acids (SFAs), which promoted the release of NETs via the TLR4-MD2/ROS signaling pathway. We further revealed that NETs potentiate IL-17 inflammation, especially γδT17-mediated immune responses, in obesity-exacerbated psoriasis patients. Moreover, SFAs induced a decreased response to anti-IL17A treatment in psoriasis-like mice, whereas the inhibition of NETs improved the beneficial effects of anti-IL17A in psoriasis-like mice with lipid metabolism disorders. Our findings collectively suggest that SFA-induced NETs play a critical role in the exacerbation of obesity-related psoriasis and provide potential new strategies for the clinical treatment of refractory psoriasis patients with lipid metabolism disorders.
Keywords: anti-IL17A; neutrophil extracellular traps; obesity; psoriasis; saturated fatty acids.
© 2025. The Author(s), under exclusive licence to CSI and USTC.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics: All studies involving mice were approved by the Institutional Animal Care and Use Committee of Huazhong University of Science and Technology with ethics approval number IACUC- [2022]-3147. All human clinical protocols were approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, with an ethics approval number of EC- [2023]-S053. Written informed consent was obtained from the patients before participation in the study.
Comment in
-
NETosis exacerbates skin inflammation in obese psoriasis patients.Cell Mol Immunol. 2025 Jun;22(6):690-691. doi: 10.1038/s41423-025-01287-6. Epub 2025 May 20. Cell Mol Immunol. 2025. PMID: 40394184 No abstract available.
References
-
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397:1301–15. - PubMed
-
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60. - PubMed
-
- Yu J, Zhao Q, Wang X, Zhou H, Hu J, Gu L, et al. Pathogenesis, multiomics research, and clinical treatment of psoriasis. J Autoimmun. 2022;133:102916. - PubMed
-
- Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77:287–92.e4. - PubMed
MeSH terms
Substances
Grants and funding
- 82130089/National Natural Science Foundation of China (National Science Foundation of China)
- 82103730/National Natural Science Foundation of China (National Science Foundation of China)
- 82304022/National Natural Science Foundation of China (National Science Foundation of China)
- 32070894/National Natural Science Foundation of China (National Science Foundation of China)
LinkOut - more resources
Full Text Sources
Medical
